Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 35 clinical trials
Dolutegravir-Lamivudine for na ve HIV-Infected Patients With 200 CD4/mm3

Protocol Title: DOLCE: Dolutegravir-Lamivudine for nave HIV-Infected Patients with 200 CD4/mm3 Protocol Number: FH-57 Study Objectives: To assess the antiviral activity at week 48

  • 0 views
  • 04 Oct, 2021
  • 4 locations
  • 0 views
  • 26 Jan, 2021
  • 1 location
Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)Ides

in patients with SOR to second-line antivirals Lamivudine (LAM)/ Telbivudine (LdT)/ Adefovir Dipivoxil (ADV) and its combinations with other second-line antivirals for 24 weeks, or SOR to the first

tenofovir
adefovir
chronic hepatitis
antiviral drugs
liver disease
  • 0 views
  • 21 Feb, 2022
  • 10 locations
Tenofovir Alafenamide(TAF) Reduces the Risk of Hepatocellular Carcinoma(HCC) Recurrence

, high HBV viral load is associated with the risk of HCC recurrence after surgical resection, especially on late recurrence. In one previous randomized controlled trial, patients who received lamivudine

  • 0 views
  • 19 Jul, 2021
  • 4 locations
Safety and Efficacy of Celecoxib Plus Nucleos(t)Ide Analogues on the Hepatitis B Surface Antigen of Virally Suppressed Subjects With Chronic Hepatitis B

types of antiviral drugs: α-interferons (plain and pegylated ([PEG-IFN]α-2a or α-2b) interferons) and nucleos(t)ide analogues (NUC) including lamivudine (LAM), adefovir dipivoxil (ADV), entecavir (ETV

  • 0 views
  • 07 Apr, 2022
A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults (DYNAMIC)

The purpose of this study is to evaluate the efficacy of GSK3640254 + DTG relative to lamivudine (3TC) + DTG in treatment-naïve adult participants living with human immunodeficiency virus (HIV

dolutegravir
hiv-1 rna measurement
immunodeficiency
HIV Vaccine
lamivudine
  • 0 views
  • 14 May, 2022
  • 55 locations
BFTAF Elderly Switch Study (BFTAF)

BACKGROUND: Current Kenya National Anti-retroviral (ARV) Guidelines and World Health Organization (WHO) Guidelines recommend first-line therapy of tenofovir disoproxil fumarate (TDF), lamivudine

  • 0 views
  • 22 Mar, 2022
  • 2 locations
Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Ages 4 Weeks to <12 Years and <45 kg (MK-1439-066)

part of the fixed dose combination (FDC) of DOR/lamivudine (3TC)/tenofovir disproxil fumarate (TDF) in participants ≥6 to <12 years and weighing ≥14 to <45 kg. The second primary objective is to

tenofovir
hiv-1 rna measurement
immunodeficiency
HIV Vaccine
lamivudine
  • 0 views
  • 13 Apr, 2022
  • 13 locations
Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019

Dolutegravir is a potent integrase strand transfer inhibitor. Abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) is a fixed dose combination regimen containing two nucleoside reverse transcriptase

abacavir
dolutegravir
antiviral drugs
reverse transcriptase inhibitor
integrase inhibitors
  • 188 views
  • 23 Mar, 2022
  • 15 locations
Body Composition Sub-study of the D2EFT Trial

This is a non-randomised, controlled, parallel group, sub-study of D2EFT (NCT03017872), a randomised, open-label study in approximately 1,000 HIV-infected adults failing first-line antiretroviral therapy (ART) in low-middle income countries. The sub-study will be offered to all D2EFT sites with access to DXA technology for whole-body composition analysis. Sites will offer …

ritonavir
antiretroviral
dolutegravir
darunavir
emtricitabine
  • 9 views
  • 21 Feb, 2022
  • 7 locations